Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 48Methotrexate 33Cytarabine 27fludarabine 23fludarabine phosphate 22Rituximab 22Filgrastim 21Vincristine 19Busulfan 19Whole-Body Irradiation 18Mycophenolic Acid 18Dexamethasone 18Antilymphocyte Serum 17Cyclosporine 16Etoposide 15Tacrolimus 14Melphalan 14Calcium Dobesilate 14pegaspargase 12Peripheral Blood Stem Cell Transplantation 12Doxorubicin 12Radiotherapy 11Clofarabine 11Granulocyte Colony-Stimulating Factor 10Thiotepa 9Bortezomib 9thymoglobulin 8Dasatinib 8Asparaginase 8plerixafor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Mass Spectrometry × Clear all
NCT01383447 2017-08-08

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Terminated
2 enrolled 4 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡